logo

Fortress Biotech Inc. (FBIO)



Trade FBIO now with
  Date
  Headline
1/16/2020 9:13:54 AM Fortress Biotech Announces Rare Pediatric Disease Designation For CUTX-101 For Treatment Of Menkes Disease
8/19/2019 8:16:31 AM Fortress Biotech Names Kevin Lorenz To Its Board
3/18/2019 7:39:25 AM Fortress Biotech FY Loss Attributable To Stockholders $84.1 Mln Or $1.94/Shr Vs Loss $66.9 Mln Or $1.61/Shr Last Year
1/31/2019 6:32:24 AM Alexion And Caelum Biosciences Announce Collaboration To Develop Targeted Therapy For Light Chain Amyloidosis
1/31/2019 6:32:04 AM Caelum Signs Strategic Agreement With Alexion To Advance Development Of CAEL-101 For Light Chain Amyloidosis
1/17/2019 8:47:56 AM Aqua Metals Announces Pricing Of Underwritten Public Offering Of 4.50 Mln Shares At $1.90/shr
1/16/2019 5:19:38 PM Aqua Metals Proposes Public Offering Of Its Common Stock
12/20/2018 8:34:56 AM Mustang Bio Gets Orphan Drug Designation For MB-102 For Blastic Plasmacytoid Dendritic Cell Neoplasm
12/19/2018 9:08:32 AM Eyenovia Prices Underwritten Public Offering Of 1.20 Mln Shares At $2.45/shr
12/19/2018 8:10:15 AM Avenue Therapeutics Says First Patient Dosed In Pivotal Phase 3 Clinical Trial Of IV Tramadol
11/28/2018 8:08:56 AM Mustang Bio Reports Presentation Of MB-102 Safety And Efficacy Data At AACR Special Conference
11/20/2018 8:27:34 AM Eastside Distilling Prices Underwritten Public Offering Of 1.235 Mln Shares At $6.50/shr
11/19/2018 8:09:22 AM B. Riley Financial Enters Agreement To Acquire Fortress Biotech's Majority Stake In National Holdings
11/19/2018 8:08:44 AM B.Riley Financial To Buy Fortress Biotech For About $22.9 Mln
11/15/2018 8:35:22 PM Valeritas Announces Pricing Of $36 Mln Public Offering
11/13/2018 6:50:46 AM Cipla Subsidiary InvaGen Announces Acquisition Agreement With Avenue Therapeutics
11/9/2018 7:37:14 AM Fortress Biotech Q3 Loss Attributable To Stockholders $16.6 Mln Or $0.37shr Vs Loss $27.1 Mln Or $0.67/Shr Last Year
11/2/2018 8:10:06 AM Checkpoint Therapeutics Q3 Loss Attributable To Holders $9.3 Mln Or $0.32/Shr Vs Loss Of $5.9 Mln Or $0.26/Shr Last Year